Methods of treating type I diabetes by blocking VEGF-mediated activity

US7378095B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Jingtai Cao · White Plains, US
• Li-Hsien Wang · Somers, US
• Hsin-Chieh Lin · Taoyuan, TW
• Mark Sleeman · New York, US
• Stanley Wiegand · Croton-on-Hudson, US

Key dates

• Filing date: Jul 29, 2005
• Grant date: May 27, 2008
• Expiry date: May 25, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.